Luca Stingeni, Roberto Ravasio, Chiara Palladino, Sara Di Fino, Anna Levi, Gianluca Ronci, Paolo Gisondi
{"title":"在意大利治疗中,upadacitinib 30 mg和dupilumab 300 mg用于治疗中度重度阿特皮炎患者的费用。","authors":"Luca Stingeni, Roberto Ravasio, Chiara Palladino, Sara Di Fino, Anna Levi, Gianluca Ronci, Paolo Gisondi","doi":"10.33393/grhta.2025.3458","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"12 ","pages":"70-79"},"PeriodicalIF":0.4000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897797/pdf/","citationCount":"0","resultStr":"{\"title\":\"Costo per responder di upadacitinib 30 mg e di dupilumab 300 mg nel trattamento di pazienti con dermatite atopica moderata-grave in Italia.\",\"authors\":\"Luca Stingeni, Roberto Ravasio, Chiara Palladino, Sara Di Fino, Anna Levi, Gianluca Ronci, Paolo Gisondi\",\"doi\":\"10.33393/grhta.2025.3458\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12627,\"journal\":{\"name\":\"Global & Regional Health Technology Assessment\",\"volume\":\"12 \",\"pages\":\"70-79\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2025-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897797/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global & Regional Health Technology Assessment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33393/grhta.2025.3458\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global & Regional Health Technology Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33393/grhta.2025.3458","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
期刊介绍:
Global & Regional Health Technology Assessment (GRHTA) is a peer-reviewed, open access journal which aims to promote health technology assessment and economic evaluation, enabling choices among alternative therapeutical paths or procedures with different clinical and economic outcomes. GRHTA is a unique journal having three different editorial boards who focus on their respective geographical expertise.